US Broker Ratings

Sionna Therapeutics, Inc. (SION) Stock Analysis: A Potential 140% Upside in the Biotech Space

Sionna Therapeutics, Inc. (NASDAQ: SION), a trailblazer in the biotechnology sector, is capturing the attention of investors with its promising portfolio of cystic fibrosis (CF) treatments. Headquartered in Waltham, Massachusetts,..

AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Potential 255% Upside for Investors

Investors with an eye for high-growth potential in the biotechnology sector should take a closer look at AbCellera Biologics Inc. (NASDAQ: ABCL), a pioneering company dedicated to discovering and developing..

Ardelyx, Inc. (ARDX) Stock Analysis: Unpacking a 196.7% Potential Upside with Strong Buy Ratings

Ardelyx, Inc. (NASDAQ: ARDX), a biotechnology company headquartered in Waltham, Massachusetts, is capturing the attention of investors with its promising pipeline in the healthcare sector. With a current market capitalization..

Rocket Pharmaceuticals (RCKT) Stock Analysis: Potential 242% Upside Amidst Challenges

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a late-stage biotechnology firm, is making headlines with a potential upside of 242.96%, according to the latest analyst ratings. With a current price of $2.77,..

Embecta Corp. (EMBC) Stock Analysis: Can This Medical Device Innovator’s 77.86% Upside Potential Entice Investors?

Embecta Corp. (EMBC), a distinguished player in the healthcare sector, specializes in medical instruments and supplies with a pronounced focus on diabetes management solutions. With a market capitalization of $583.26..

Pharming Group N.V. (PHAR) Stock Analysis: Exploring a 170% Upside Potential with Groundbreaking Biotech Innovations

For investors with an eye on the healthcare sector, Pharming Group N.V. (PHAR) represents a compelling opportunity within the biotechnology industry. Headquartered in Leiden, Netherlands, Pharming Group is at the..

Arbutus Biopharma (ABUS) Stock Analysis: Exploring a Potential 57% Upside in the Biotech Sector

For investors with a keen eye on the healthcare sector, Arbutus Biopharma Corporation (NASDAQ: ABUS) presents an intriguing opportunity. This clinical-stage biopharmaceutical company is leading the charge in developing novel..

Savara, Inc. (SVRA) Investor Outlook: Biotech Stock with a 196.74% Upside Potential

Savara, Inc. (SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, is capturing the attention of investors with its impressive potential for growth. Despite its current stock price of..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Exploring a Potential 142% Upside in Biotech Innovation

Nurix Therapeutics, Inc. (NRIX), a prominent player in the biotechnology sector, has been garnering considerable attention from investors, thanks to its promising pipeline and strategic collaborations. As a clinical-stage biopharmaceutical..

InMode Ltd. (INMD) Stock Analysis: Exploring an 18.9% Upside Potential Amidst Healthcare Advances

In the ever-evolving landscape of medical devices, InMode Ltd. (NASDAQ: INMD) stands out with its innovative approach to aesthetic medical technologies. Headquartered in Yokne’am, Israel, and operating globally, InMode has..

Gyre Therapeutics, Inc. (GYRE)

⚠️ No article content returned.

..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A 131% Upside Potential in Biotech Innovation

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stands out in the biotechnology sector as a clinical-stage biopharmaceutical company with a focus on developing treatments for central nervous system (CNS) disorders. With..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: A Biotech with Potential 302.88% Upside

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN), a promising player in the biotechnology sector, captures the attention of investors with its impressive potential upside of 302.88%, according to analyst ratings. Operating..

iRadimed Corporation (IRMD) Stock Analysis: Unveiling a 17.63% Potential Upside with Strong Buy Ratings

For individual investors eyeing the healthcare sector, iRadimed Corporation (NASDAQ: IRMD) presents a compelling opportunity. This medical device company specializes in MRI-compatible medical devices, a niche but essential market, contributing..

SI-BONE, Inc. (SIBN) Stock Analysis: Unpacking a 29% Potential Upside in the Medical Device Sector

SI-BONE, Inc. (NASDAQ: SIBN), a prominent player in the healthcare sector, stands out in the medical device industry with a focus on addressing musculoskeletal disorders of the sacropelvic anatomy. As..

CareDx, Inc. (CDNA) Stock Analysis: Exploring a 56.11% Potential Upside in the Growing Transplant Diagnostics Market

CareDx, Inc. (NASDAQ: CDNA) stands at the forefront of innovation within the healthcare sector, particularly in the diagnostics and research industry. The company, which specializes in providing diagnostic solutions for..

Nuvation Bio Inc. (NUVB) Stock Analysis: Unpacking a 215.86% Potential Upside in Biotech

As the biopharmaceutical landscape continues to evolve, Nuvation Bio Inc. (NASDAQ: NUVB) emerges as a compelling player in the oncology sector with an enticing potential upside of 215.86%. This clinical-stage..

GH Research PLC (GHRS) Stock Analysis: Exploring a Potential 162.83% Upside with Promising Depression Treatments

GH Research PLC (NASDAQ: GHRS), an innovative player in the biotechnology sector, is capturing investor attention with its remarkable potential upside of 162.83%. This Dublin-based clinical-stage biopharmaceutical company is at..

Avadel Pharmaceuticals (AVDL) Stock Analysis: Healthcare Innovator with an 80% Upside Potential

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a biopharmaceutical company based in Dublin, Ireland, known for its focus on innovative therapies in the healthcare sector. The company’s flagship product, LUMRYZ, is..

CureVac N.V. (CVAC) Investor Outlook: Eyeing a 41% Upside in the Biotechnology Sector

CureVac N.V. (NASDAQ: CVAC), a pioneering biopharmaceutical entity based in Tübingen, Germany, stands at the forefront of mRNA technology in the biotechnology sector. With a market capitalization of $1 billion,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds